This article is more than 5 years old. Information may no longer be current.

VIDEO: Anabasum shows acceptable safety, tolerability for diffuse system sclerosis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robert F. Spiera, MD, of the Hospital for Special Surgery, spoke about the safety and efficacy of anabasum, a cannabinoid receptor type 2 agonist, for the treatment of diffuse systemic sclerosis.

Spiera said in this phase 2 study of 42 patients, anabasum had acceptable safety in diffuse systemic sclerosis with evidence of clinical benefit. Additionally, there were a strong correlation in the ACR Combined Response Index in Diffuse Cutaneous System Sclerosis scores, which was the primary efficacy outcome.